Learn more about USP's COVID vaccine efforts:
USP.org/COVID-19/Vaccines
To build public trust and confidence in innovative technologies, they must be good quality, safe and effective. To address the need for a common set of methods for determining quality of viral vectored vaccines, USP will continue to actively monitor scientific and regulatory developments in the field of viral vectored vaccines to ensure its efforts remain relevant, timely, and aligned with the evolving needs of the industry and public health priorities. As part of this commitment, USP will engage in ongoing, collaborative conversations with a broad range of stakeholders, including manufacturers, regulatory authorities, academic researchers, and other scientific organizations—to gather insights, share progress, and foster a transparent and inclusive approach to standard development.
USP welcomes public comments on Analytical Procedures for Viral Vectored Vaccines Quality.
Submit the form below to receive the draft guidelines
Read and review the draft guidelines
Submit your comments to USPVaccines@usp.org
USP Vaccine Quality Draft Guidelines
Analytical Procedures for Viral Vectored Vaccine Quality - Draft Guidelines 2nd Edition
USP welcomes the continued submission of alternative analytical methods along with supporting documentation, including validation documents to strengthen the scientific foundation of the draft guidelines and support the development of high-quality, fit-for-purpose standards that benefit the broader biopharmaceutical community.
Deadline for feedback is February 21, 2026
Submit the form to receive the resource.
